David A. Siegel Cidara Therapeutics, Inc. Transaction History

Two Sigma Advisers, LP

  • $41.3 Billion
  • Q3 2024

Shares

18 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 15, 2024
SELL
$0.64 - $0.92 $10,560 - $15,180
-16,500 Reduced 40.84%
23,900 $21,000
Q4 2023

Feb 14, 2024
SELL
$0.68 - $0.97 $10,064 - $14,356
-14,800 Reduced 26.81%
40,400 $31,000
Q3 2023

Nov 14, 2023
SELL
$0.77 - $1.16 $16,478 - $24,824
-21,400 Reduced 27.94%
55,200 $51,000
Q2 2023

Aug 14, 2023
BUY
$1.01 - $1.42 $13,130 - $18,460
13,000 Added 20.44%
76,600 $86,000
Q1 2023

May 15, 2023
BUY
$0.75 - $1.98 $28,350 - $74,844
37,800 Added 146.51%
63,600 $80,000
Q4 2022

Feb 14, 2023
SELL
$0.48 - $13.08 $1,152 - $31,392
-2,400 Reduced 8.51%
25,800 $19,000
Q3 2022

Nov 14, 2022
SELL
$0.45 - $13.0 $4,722 - $136,422
-10,494 Reduced 27.12%
28,200 $18,000
Q2 2022

Aug 15, 2022
SELL
$0.43 - $0.91 $49,751 - $105,287
-115,700 Reduced 74.94%
38,694 $19,000
Q1 2022

May 16, 2022
SELL
$0.67 - $1.39 $262,573 - $544,741
-391,900 Reduced 71.74%
154,394 $129,000
Q4 2021

Feb 14, 2022
BUY
$1.18 - $2.18 $91,686 - $169,386
77,700 Added 16.58%
546,294 $694,000
Q3 2021

Nov 15, 2021
BUY
$1.48 - $2.35 $633,440 - $1.01 Million
428,000 Added 1054.34%
468,594 $1.05 Million
Q2 2021

Aug 16, 2021
SELL
$1.87 - $2.7 $90,134 - $130,140
-48,200 Reduced 54.28%
40,594 $82,000
Q1 2021

May 17, 2021
BUY
$2.06 - $3.01 $111,528 - $162,961
54,140 Added 156.23%
88,794 $236,000
Q4 2020

Feb 16, 2021
SELL
$1.99 - $3.25 $33,312 - $54,405
-16,740 Reduced 32.57%
34,654 $69,000
Q3 2020

Nov 16, 2020
SELL
$2.85 - $4.1 $103,341 - $148,666
-36,260 Reduced 41.37%
51,394 $146,000
Q2 2020

Aug 14, 2020
BUY
$2.39 - $4.0 $121,412 - $203,200
50,800 Added 137.84%
87,654 $323,000
Q1 2020

May 15, 2020
BUY
$1.74 - $4.26 $39,765 - $97,358
22,854 Added 163.24%
36,854 $91,000
Q4 2019

Feb 14, 2020
BUY
$1.77 - $3.84 $24,780 - $53,760
14,000 New
14,000 $54,000

About Cidara Therapeutics, Inc.

CDTX Quotes by TradingView
  • Ticker CDTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 70,075,696
  • Market Cap $1.63B
  • Description
  • Cidara Therapeutics, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of long-acting anti-infectives for the treatment and prevention of infectious diseases and oncology in the United States. The company's lead product candidate is rezafungin acetate, a novel molecule in the echinocandin class of antifu...
More about CDTX
Track David A. Siegel's Portfolio

Track David A. Siegel Portfolio

Follow David A. Siegel (Two Sigma Advisers, LP) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

News

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email